ArticleClinical rheumatology2025
Burden and determinants of cognitive impairment in patients with systemic lupus erythematosus patients: a cross-sectional study from a tertiary care centre in South India.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo estimate the prevalence of cognitive impairment (CI) in patients with SLE and to determine factors associated with its occurrence.
methodsPatients with SLE diagnosed as per SLICC-2012 criteria attending rheumatology outpatient clinic during their routine-care visits were included between 2021 and 2022. They underwent screening for anxiety and depression using GAD7 and PHQ9, respectively. Montreal Cognitive Assessment (MoCA) Questionnaire was administered to all patients and matched healthy controls. Prevalence of CI and the factors associated with cognitive impairment were evaluated.
resultsWe included 160 patients with SLE [mean age 28.1 ± 7.7 years, F:M::15:1] and healthy controls. Median disease duration of SLE was 30 (IQR 16.47) months and 33 (20.6%) had prior NPSLE events. Overall, half of SLE patients [N = 87 (54%)] had CI, as compared to healthy controls [N = 33 (20.6%)] (P = < 0.001), most commonly affected domain being delayed recall (N = 132, 82.5%). We found significant association of CI with older age (OR 1.09 (1.04, 1.16), lower socioeconomic status (SES) (OR 5.95 (2.04, 17.3), and lower education levels (OR 2.16 (1.02, 4.56). Anxiety and depression demonstrated a significant association with CI in unadjusted analysis. Disease duration, cumulative glucocorticoid dose, prior NPSLE diagnosis, and anti-phospholipid antibodies were not associated with occurrence of CI.
conclusionsCI was detected in more than half of SLE patients. Higher age, lower SES and education, anxiety, depression and not lupus specific factors were associated with the occurrence of cognitive dysfunction. Key Points • Our study revealed a significantly higher prevalence of CI in SLE patients, compared to healthy controls, as assessed by the MoCA questionnaire. • While traditional lupus-specific factors like disease duration, glucocorticoid usage, prior NPSLE events and the presence of anti-phospholipid antibody were not independently associated with CI, our study found that older age, lower socioeconomic status and lower education level were significant risk factors. • Routine screening and comprehensive assessment of cognitive function is important in all SLE patients, regardless of NPSLE history.
Indexed as
Identifiers
40784915What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.